Another HAE drug acquired along with rare disease specialist Viropharma in January - Cinryze (C1 esterase inhibitor) - added $130m to the pot, which was a 37 per cent increase on the same period ...

Shire also announced, on January 24th, that it had completed the merger of ViroPharma with one of its subsidiaries. Shire taps ex-investment banker Susan Kilsby to chair its board (FiercePharma).

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-b ...

New York, USA, March 04, 2025 (GLOBE NEWSWIRE) -- Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight The ...

Uncomplicated skin infections account for almost 200 million physician-office visits in the USA annually. Treating these infections is estimated to cost in excess of US$350 million each year. The ...

Am J Health Syst Pharm. 2012;69(11):933-943. Based on current clinical trials reporting fewer recurrences among patients treated with fidaxomicin in which the non-NAP1/BI/027 strains were isolated ...

10 Central and Peripheral Degenerative Neuropathy Unit, IRCCS Foundation, Carlo Besta Neurological Institute, Milan, Italy Background We reported that 6-month therapy with intravenous immunoglobulin ...